[go: up one dir, main page]

AU1087299A - Non-integrating dna vector of retroviral origin having high-protein expres sion, and secreted immunogenic antigens - Google Patents

Non-integrating dna vector of retroviral origin having high-protein expres sion, and secreted immunogenic antigens

Info

Publication number
AU1087299A
AU1087299A AU10872/99A AU1087299A AU1087299A AU 1087299 A AU1087299 A AU 1087299A AU 10872/99 A AU10872/99 A AU 10872/99A AU 1087299 A AU1087299 A AU 1087299A AU 1087299 A AU1087299 A AU 1087299A
Authority
AU
Australia
Prior art keywords
dna vector
immunogenic antigens
expres sion
integrating dna
retroviral origin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU10872/99A
Inventor
Prasert Auewarakul
Natth Bharmarapravati
Yichen Lu
Neal Touzjian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INSTITUTE FOR VACCINE DEVELOPMENT
Celldex Therapeutics Inc
Original Assignee
INST VACCINE DEV
Avant Immunotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INST VACCINE DEV, Avant Immunotherapeutics Inc filed Critical INST VACCINE DEV
Publication of AU1087299A publication Critical patent/AU1087299A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU10872/99A 1997-10-14 1998-10-14 Non-integrating dna vector of retroviral origin having high-protein expres sion, and secreted immunogenic antigens Abandoned AU1087299A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6189497P 1997-10-14 1997-10-14
US60061894 1997-10-14
PCT/US1998/021739 WO1999019501A1 (en) 1997-10-14 1998-10-14 Non-integrating dna vector of retroviral origin having high-protein expression, and secreted immunogenic antigens

Publications (1)

Publication Number Publication Date
AU1087299A true AU1087299A (en) 1999-05-03

Family

ID=22038839

Family Applications (1)

Application Number Title Priority Date Filing Date
AU10872/99A Abandoned AU1087299A (en) 1997-10-14 1998-10-14 Non-integrating dna vector of retroviral origin having high-protein expres sion, and secreted immunogenic antigens

Country Status (2)

Country Link
AU (1) AU1087299A (en)
WO (1) WO1999019501A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531123B1 (en) 1997-05-01 2003-03-11 Lung-Ji Chang Lentiviral vectors
WO2000000600A2 (en) * 1997-09-22 2000-01-06 Chang Lung Ji Lentiviral vectors, comprising modified major donor splice sites and major packaging signals
EP1228095B1 (en) 1999-10-22 2008-04-09 Sanofi Pasteur Limited Modified gp100 and uses thereof
US7851212B2 (en) 2000-05-10 2010-12-14 Sanofi Pasteur Limited Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
US6867420B2 (en) 2002-06-03 2005-03-15 The Regents Of The University Of California Solid-state detector and optical system for microchip analyzers
WO2004065575A2 (en) * 2003-01-15 2004-08-05 Research Institute For Genetic And Human Therapy (Right) Dna compositon and uses thereof
GB0526211D0 (en) * 2005-12-22 2006-02-01 Oxford Biomedica Ltd Viral vectors
WO2010009465A2 (en) * 2008-07-18 2010-01-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Htlv-ii vector and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174666B1 (en) * 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US6080408A (en) * 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
AU4740096A (en) * 1994-12-30 1996-07-24 Chiron Viagene, Inc. Direct administration of gene delivery vehicles at multiple sites
FR2747046B1 (en) * 1996-04-05 1998-06-19 Univ Paris Curie NEW PLASMOVIRUS VACCINES

Also Published As

Publication number Publication date
WO1999019501A1 (en) 1999-04-22

Similar Documents

Publication Publication Date Title
AU8828598A (en) Retrovirus and viral vectors
AU1829997A (en) Mixture of recombinant vaccinia vectors as polyenv vaccines for hiv
AU9319198A (en) Methods and vector constructs useful for production of recombinant aav
AU2678097A (en) Targeted viral vectors
AU3760100A (en) Immunostimulatory nucleic acids and antigens
AU6020598A (en) Dna sequences, vectors, and fusion polypeptides for secretion of polypeptides infilamentous fungi
AU1498497A (en) Isolation and sequencing of the hazel FAD2-N gene
AU7332198A (en) Lentivirus based vector and vector system
AU6700598A (en) Intron-mediated recombinant techniques and reagents
AU2809897A (en) Novel human cytomegalovirus dna constructs and uses therefor
AU3648697A (en) Thermostable mutl genes and proteins and uses therefor
AU3882997A (en) Human telomerase gene
AU2548097A (en) Formulations of ob protein
AU6585498A (en) Novel uncoupling protein and methods of use
AU1087299A (en) Non-integrating dna vector of retroviral origin having high-protein expres sion, and secreted immunogenic antigens
AU6795798A (en) Composite antenna for duplexer-free duplex operation terminals and method
AU4401297A (en) Improved retroviral vectors for gene therapy
AU8396198A (en) Axin gene and uses thereof
AU1260297A (en) Flat sling coupling constructions
AU1233399A (en) Colorant preparations
AU3288497A (en) Mammalian tolloid-like gene and protein
AU3212197A (en) Modular assembly retroviral vectors and uses thereof
AU8578598A (en) Anti-inflammatory factor, method of isolation, and use
AU3552797A (en) Vaccine preparations
AU6853498A (en) Flutamide preparations and method for manufacturing the same

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase